Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPO-TRAUMA
2023-506081-31-00Phase 3Authorised
- Sponsor
- University College Dublin
- Start
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in Physical trauma comparing Epoetin alfa arm with Placebo arm (2 arms). Primary endpoint: Composite of mortality and severe disability at six months. Planned start Mar 2022; status: authorised.
02
Drugs
epoetin alfa
03
Conditions
Physical trauma
Beyond the preview
Go deeper on 2023-506081-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506081-31-00.